Yuan Zong1, Changsong Qi, Zhi Peng, Lin Shen, Jun Zhou. 1. From the Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
Abstract
OBJECTIVES: Acinar cell carcinoma of the pancreas is a rare tumor with limited data. We aim to evaluate the characteristics, treatments, and outcomes of pancreatic acinar cell carcinoma after 2005. METHODS: We retrospectively reviewed patients with pancreatic acinar cell carcinoma treated in Peking University Cancer Hospital and Institute (2005-2018) and identified cases from Surveillance, Epidemiology, and End Results database (2005-2015). RESULTS: A total of 306 cases in our institute (n = 11) and Surveillance, Epidemiology, and End Results database (n = 295) were identified. The median age was 67 years, and 73.5% were male. The 5-year survival was 36.8% for all patients (median, 27 months). About 37% underwent surgical resection. The 5-year survival was 65.6% for resected patients as compared with 16.9% for unresected ones (P < 0.0001). Among locoregional and metastatic diseases, surgery significantly prolonged survival as well (P = 0.0003). Stage IV patients who received chemotherapy had a better survival than those without it (median, 16 vs 3 months; P = 0.0019). Aging, stage IV, and no surgery were independent predictors of poor overall survival. CONCLUSIONS: For pancreatic acinar cell carcinoma, surgery is a potentially curative treatment contributing to long-term survival and suggested even in advanced diseases. Chemotherapy improved survival for metastatic patients.
OBJECTIVES:Acinar cell carcinoma of the pancreas is a rare tumor with limited data. We aim to evaluate the characteristics, treatments, and outcomes of pancreatic acinar cell carcinoma after 2005. METHODS: We retrospectively reviewed patients with pancreatic acinar cell carcinoma treated in Peking University Cancer Hospital and Institute (2005-2018) and identified cases from Surveillance, Epidemiology, and End Results database (2005-2015). RESULTS: A total of 306 cases in our institute (n = 11) and Surveillance, Epidemiology, and End Results database (n = 295) were identified. The median age was 67 years, and 73.5% were male. The 5-year survival was 36.8% for all patients (median, 27 months). About 37% underwent surgical resection. The 5-year survival was 65.6% for resected patients as compared with 16.9% for unresected ones (P < 0.0001). Among locoregional and metastatic diseases, surgery significantly prolonged survival as well (P = 0.0003). Stage IV patients who received chemotherapy had a better survival than those without it (median, 16 vs 3 months; P = 0.0019). Aging, stage IV, and no surgery were independent predictors of poor overall survival. CONCLUSIONS: For pancreatic acinar cell carcinoma, surgery is a potentially curative treatment contributing to long-term survival and suggested even in advanced diseases. Chemotherapy improved survival for metastatic patients.
Authors: Lena Dreikhausen; Nadine Schulte; Sebastian Belle; Philip Weidner; Johannes Moersdorf; Christoph Reissfelder; Matthias P Ebert; Tianzuo Zhan Journal: Visc Med Date: 2021-03-29
Authors: Ekaterina Petrova; Joachim Wellner; Anne K Nording; Rüdiger Braun; Kim C Honselmann; Louisa Bolm; Richard Hummel; Monika Klinkhammer-Schalke; Sylke Ruth Zeissig; Kees Kleihues van Tol; Sylvia Timme-Bronsert; Peter Bronsert; Sergey Zemskov; Tobias Keck; Ulrich Friedrich Wellner Journal: Cancers (Basel) Date: 2021-12-04 Impact factor: 6.639
Authors: S M Haenen; J A M G Tol; S C J van Steen; O R Busch; A Farine Sarasqueta; S Roshani; A Wolkerstorfer; M M D van der Linden; J W Wilmink; H C Post; M G Besselink Journal: J Med Case Rep Date: 2022-10-05